Liminatus Pharma shares surge 14.15% intraday as clinical-stage immuno-oncology company advances IBA101, a humanized anti-CD47 monoclonal antibody for advanced solid tumors.

Liminatus Pharma surged 14.15% intraday, with the company announcing its lead candidate IBA101, a humanized anti-CD47 monoclonal antibody for advanced solid cancers like non-small cell lung cancer. The company is a pre-clinical stage immuno-oncology firm focused on developing novel immunomodulatory cancer therapies, primarily targeting advanced solid tumors through its pipeline of innovative treatments.